Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

FPR2/ALX

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_590

Synonyms

Historical Background

The FPR2/ALX receptor is a member of the formyl peptide receptor (FPR) superfamily which in humans also includes formyl peptide receptor 1 (FPR1) and formyl peptide receptor 3 (FPR3). Recent interest in this specific receptor reflects its intriguing anti-inflammatory and proresolving bioactions in contrast to other FPR family members (Serhan 2007; Maderna et al. 2010). FPR2/ALX was identified as a specific receptor for lipoxin A4 (LXA4) in 1992 (Fiore et al. 1992). Using radiolabeled [11,12-3H]LXA4 and human polymorphonuclear leukocytes (PMNs) in which LXA4-mediated action had previously been identified, specific stereoselective binding with a Kd of approximately 0.5 nM was demonstrated. Modulation of [11,12-3H]LXA4binding by guanosine analogs indicated that this binding site was a G-protein-coupled receptor...

This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors thank Dr. Aisling Kennedy and Dr. Eoin Brennan for their helpful comments. Work in the authors’ lab is funded by Science Foundation Ireland, The Health Research Board, and The Government of Ireland Programme for Research in Third-Level Institutions. Karen Nolan is an IRCSET postgraduate Scholar.

References

  1. Baker N, O’Meara SJ, Scannell M, Maderna P, Godson C. Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. J Immunol. 2009;182:3819–26.PubMedPubMedCentralGoogle Scholar
  2. Borgeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O’Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C. Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. FASEB J. 2011;25:2967–79.PubMedPubMedCentralGoogle Scholar
  3. Brancaleone V, Dalli J, Bena S, Flower RJ, Cirino G, Perretti M. Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. J Immunol. 2011;186:4905–14.PubMedPubMedCentralGoogle Scholar
  4. Burli RW, Xu H, Zou X, Muller K, Golden J, Frohn M, Adlam M, Plant MH, Wong M, McElvain M, Regal K, Viswanadhan VN, Tagari P, Hungate R. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2006;16:3713–8.PubMedPubMedCentralGoogle Scholar
  5. Chiang N, Fierro IM, Gronert K, Serhan CN. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med. 2000;191:1197–208.PubMedPubMedCentralGoogle Scholar
  6. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev. 2006;58:463–87.PubMedPubMedCentralGoogle Scholar
  7. Cui Y, Le Y, Yazawa H, Gong W, Wang JM. Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer’s disease. J Leukoc Biol. 2002;72:628–35.PubMedPubMedCentralGoogle Scholar
  8. Devchand PR, Arita M, Hong S, Bannenberg G, Moussignac RL, Gronert K, Serhan CN. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J. 2003;17:652–9.PubMedPubMedCentralGoogle Scholar
  9. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, D’Acquisto F, Buckingham JC, Perretti M, Flower RJ. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol. 2010;184:2611–9.PubMedPubMedCentralGoogle Scholar
  10. El Kebir D, Jozsef L, Filep JG. Opposing regulation of neutrophil apoptosis through the formyl peptide receptor-like 1/lipoxin A4 receptor: implications for resolution of inflammation. J Leukoc Biol. 2008;84:600–6.PubMedPubMedCentralGoogle Scholar
  11. Facio Jr FN, Sena AA, Araujo LP, Mendes GE, Castro I, Luz MA, Yu L, Oliani SM, Burdmann EA. Annexin 1 mimetic peptide protects against renal ischemia/reperfusion injury in rats. J Mol Med. 2011;89:51–63.PubMedPubMedCentralGoogle Scholar
  12. Filep JG, Khreiss T, Jozsef L. Lipoxins and aspirin-triggered lipoxins in neutrophil adhesion and signal transduction. Prostaglandins Leukot Essent Fatty Acids. 2005;73:257–62.PubMedPubMedCentralGoogle Scholar
  13. Fiore S, Ryeom SW, Weller PF, Serhan CN. Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J Biol Chem. 1992;267:16168–76.PubMedPubMedCentralGoogle Scholar
  14. Gewirtz AT, McCormick B, Neish AS, Petasis NA, Gronert K, Serhan CN, Madara JL. Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. J Clin Invest. 1998;101(9):1860–9.PubMedPubMedCentralGoogle Scholar
  15. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol. 2000;164:1663–7.PubMedPubMedCentralGoogle Scholar
  16. Guilford WJ, Bauman JG, Skuballa W, Bauer S, Wei GP, Davey D, Schaefer C, Mallari C, Terkelsen J, Tseng JL, Shen J, Subramanyam B, Schottelius AJ, Parkinson JF. Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J Med Chem. 2004;47(8):2157–65.PubMedPubMedCentralGoogle Scholar
  17. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood. 2003;101(4):1572–81.PubMedPubMedCentralGoogle Scholar
  18. Hecht I, Rong J, Sampaio AL, Hermesh C, Rutledge C, Shemesh R, Toporik A, Beiman M, Dassa L, Niv H, Cojocaru G, Zauberman A, Rotman G, Perretti M, Vinten-Johansen J, Cohen Y. A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects. J Pharmacol Exp Ther. 2009;328:426–34.PubMedPubMedCentralGoogle Scholar
  19. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA. 2010;107:1660–5.PubMedPubMedCentralGoogle Scholar
  20. Leonard MO, Hannan K, Burne MJ, Lappin DW, Doran P, Coleman P, Stenson C, Taylor CT, Daniels F, Godson C, Petasis NA, Rabb H, Brady HR. 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J Am Soc Nephrol. 2002;13:1657–62.PubMedPubMedCentralGoogle Scholar
  21. Maderna P, Cottell DC, Berlasconi G, Petasis NA, Brady HR, Godson C. Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am J Pathol. 2002;160(6):2275–83.PubMedPubMedCentralGoogle Scholar
  22. Maderna P, Godson C. Lipoxins: resolutionary road. Br J Pharmacol. 2009;158:947–59.PubMedPubMedCentralGoogle Scholar
  23. Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M, Godson C. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J. 2010;24:4240–9.PubMedPubMedCentralGoogle Scholar
  24. Martins V, Valenca SS, Farias-Filho FA, Molinaro R, Simoes RL, Ferreira TP, Silva PM, Hogaboam CM, Kunkel SL, Fierro IM, Canetti C, Benjamim CF. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J Immunol. 2009;182:5374–81.PubMedPubMedCentralGoogle Scholar
  25. McMahon B, Stenson C, McPhillips F, Fanning A, Brady HR, Godson C. Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J Biol Chem. 2000;275(36):27566–75.PubMedPubMedCentralGoogle Scholar
  26. McMahon B, Mitchell D, Shattock R, Martin F, Brady HR, Godson C. Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J. 2002;16(13):1817–9.PubMedPubMedCentralGoogle Scholar
  27. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, Petasis NA, Erwig L, Rees AJ, Savill J, Brady HR, Godson C. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol. 2002;13(10):2497–507.PubMedPubMedCentralGoogle Scholar
  28. Mitchell D, O’Meara SJ, Gaffney A, Crean JK, Kinsella BT, Godson C. The Lipoxin A4 receptor is coupled to SHP-2 activation: implications for regulation of receptor tyrosine kinases. J Biol Chem. 2007;282:15606–18.PubMedPubMedCentralGoogle Scholar
  29. Norling LV, Spite M, Yang R, Flower RJ, Perretti M, Serhan CN. Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol. 2011;186:5543–7.PubMedPubMedCentralGoogle Scholar
  30. O’Sullivan TP, Vallin KS, Shah ST, Fakhry J, Maderna P, Scannell M, Sampaio AL, Perretti M, Godson C, Guiry PJ. Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J Med Chem. 2007;50:5894–902.PubMedPubMedCentralGoogle Scholar
  31. Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009;9:62–70.PubMedPubMedCentralGoogle Scholar
  32. Rautenberg M, Joo HS, Otto M, Peschel A. Neutrophil responses to staphylococcal pathogens and commensals via the formyl peptide receptor 2 relates to phenol-soluble modulin release and virulence. FASEB J. 2011;25:1254–63.PubMedPubMedCentralGoogle Scholar
  33. Rodgers K, McMahon B, Mitchell D, Sadlier D, Godson C. Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am J Pathol. 2005;167(3):683–94.PubMedPubMedCentralGoogle Scholar
  34. Scannell M, Flanagan MB, de Stefani A, Wynne KJ, Cagney G, Godson C, Maderna P. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol. 2007;178:4595–605.PubMedPubMedCentralGoogle Scholar
  35. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101–37.PubMedPubMedCentralGoogle Scholar
  36. Sun YP, Tjonahen E, Keledjian R, Zhu M, Yang R, Recchiuti A, Pillai PS, Petasis NA, Serhan CN. Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs. Prostaglandins Leukot Essent Fatty Acids. 2009;81:357–66.PubMedPubMedCentralGoogle Scholar
  37. Wan M, Godson C, Guiry PJ, Agerberth B, Haeggstrom JZ. Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1. FASEB J. 2011;25:1697–705.PubMedPubMedCentralGoogle Scholar
  38. Wu SH, Lu C, Dong L, Zhou GP, He ZG, Chen ZQ. Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int. 2005;68(1):35–46.PubMedPubMedCentralGoogle Scholar
  39. Wu SH, Wu XH, Lu C, Dong L, Chen ZQ. Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor. Am J Respir Cell Mol Biol. 2006;34(1):65–72.PubMedPubMedCentralGoogle Scholar
  40. Wu J, Wang A, Min Z, Xiong Y, Yan Q, Zhang J, Xu J, Zhang S. Lipoxin A4 inhibits the production of proinflammatory cytokines induced by beta-amyloid in vitro and in vivo. Biochem Biophys Res Commun. 2011;408:382–7.PubMedPubMedCentralGoogle Scholar
  41. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN, Murphy PM. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev. 2009;61:119–61.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.UCD Diabetes Research Centre, UCD Conway InstituteSchool of Medicine and Medical Sciences, University College DublinDublinIreland